<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994743</url>
  </required_header>
  <id_info>
    <org_study_id>CORT113176-653</org_study_id>
    <secondary_id>2021-002456-36</secondary_id>
    <nct_id>NCT04994743</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants</brief_title>
  <official_title>Multiple Dose Safety, Tolerability, Plasma and Cerebrospinal-Fluid Pharmacokinetic Study of Oral Doses of CORT113176</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety, tolerability, and pharmacokinetic study in 2 cohorts of healthy male&#xD;
      participants with an option for an additional cohort. Cohorts 1 and 2 will receive once daily&#xD;
      by mouth CORT113176 150 mg and 300 mg, respectively, for 14 days under fed conditions.&#xD;
      Progression from Cohort 1 to Cohort 2 will be done based on the safety and tolerability&#xD;
      outcome in Cohort 1 and after Cohort 1 has received the study drug for at least 7 days. The&#xD;
      optional Cohort 3 may receive a higher dose that will not exceed CORT113176 450 mg once daily&#xD;
      by mouth for 14 days under fed conditions. The progression from Cohort 2 to the optional&#xD;
      cohort (Cohort 3) will be based on the same precautions as with the progression from Cohort 1&#xD;
      to Cohort 2. Each participant will undergo safety evaluations. Pharmacokinetics of CORT113176&#xD;
      will be assessed in plasma and cerebrospinal fluid (CSF) samples. Pharmacodynamic assessments&#xD;
      will include the measurement of serum cortisol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Events</measure>
    <time_frame>Up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of CORT113176</measure>
    <time_frame>Before dosing and a pre-specified time points up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax) of Plasma CORT113176</measure>
    <time_frame>Before dosing and a pre-specified time points up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-life (t1/2) of Plasma CORT113176</measure>
    <time_frame>Before dosing and a pre-specified time points up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) of Plasma CORT113176</measure>
    <time_frame>Before dosing and a pre-specified time points up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid Concentration of CORT113176</measure>
    <time_frame>Approximately 3 and 5 hours after dosing on Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Cortisol</measure>
    <time_frame>Before and approximately 12 hours after dosing on Days 1, 7, and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Cohort 1: CORT113176 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CORT113176 150 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo matching CORT113176</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: CORT113176 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CORT113176 300 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Progression from Cohort 1 to 2 will be done based on safety and tolerability outcome from Cohort 1 and only after Cohort 1 has received study drug for ≥7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo matching CORT113176</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: CORT113176 ≥300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CORT113176 ≥300 mg not to exceed 450 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Cohort 3 is optional, and progression from Cohort 2 to 3 be done based on safety and tolerability outcome from Cohort 2 and only after Cohort 2 has received study drug for ≥7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Placebo matching CORT113176</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CORT113176</intervention_name>
    <description>CORT113176 lipid capsule formulation for oral administration</description>
    <arm_group_label>Cohort 1: CORT113176 150 mg</arm_group_label>
    <arm_group_label>Cohort 2: CORT113176 300 mg</arm_group_label>
    <arm_group_label>Cohort 3: CORT113176 ≥300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching CORT113176</intervention_name>
    <description>Placebo matching CORT113176 lipid capsule formulation for oral administration</description>
    <arm_group_label>Cohort 1: Placebo matching CORT113176</arm_group_label>
    <arm_group_label>Cohort 2: Placebo matching CORT113176</arm_group_label>
    <arm_group_label>Cohort 3: Placebo matching CORT113176</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 30.0 kg/m^2, inclusive&#xD;
&#xD;
          -  Body weight ≤100 kg.&#xD;
&#xD;
          -  Must agree to adhere to the requirements on contraception, exposure to sexual&#xD;
             partners, and sperm donation as defined in the protocol&#xD;
&#xD;
          -  Additional criteria apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any investigational drug in a clinical research study within the last 90 days&#xD;
&#xD;
          -  History of alcohol abuse or drug addiction (including soft drugs like cannabis&#xD;
             products) within past 5 years.&#xD;
&#xD;
          -  Regular alcohol consumption&#xD;
&#xD;
          -  Positive drug, nicotine (cotinine), or alcohol screen&#xD;
&#xD;
          -  Current smokers, user of e-cigarettes and nicotine replacement products and those who&#xD;
             have used these products within the last 3 months&#xD;
&#xD;
          -  Have a pregnant partner&#xD;
&#xD;
          -  Clinically significant abnormal clinical chemistry, hematology (including&#xD;
             coagulation), or urinalysis&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  Positive nasopharyngeal polymerase chain reaction (PCR) test for severe acute&#xD;
             respiratory syndrome Covid Virus-2 (SARS-CoV-2) on Day -1 or within 8 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Contact with COVID-19 positive (or suspected) persons within 14 days prior to first&#xD;
             dose&#xD;
&#xD;
          -  Active renal and/or hepatic disease&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, endocrine,&#xD;
             metabolic, respiratory, gastrointestinal (GI), neurological, or psychiatric disorder&#xD;
&#xD;
          -  Abnormalities in brain and lumbar spine, or other medical or surgical conditions or&#xD;
             clinically significant abnormal findings, for which lumbar puncture is contraindicated&#xD;
&#xD;
          -  History of clinically significant back pain, back pathology and/or back injury&#xD;
&#xD;
          -  History of significant active bleeding or coagulation disorder or have taken&#xD;
             non-steroidal anti-inflammatory drugs or other drugs that affect coagulation or&#xD;
             platelet function within 14 days prior to lumbar puncture&#xD;
&#xD;
          -  Allergy to lidocaine (Xylocaine®) or its derivatives&#xD;
&#xD;
          -  Any form of cancer within the 5 years (exceptions apply)&#xD;
&#xD;
          -  History and/or symptoms of adrenal insufficiency&#xD;
&#xD;
          -  Have a condition that could be aggravated by glucocorticoid antagonism&#xD;
&#xD;
          -  Donation or loss of greater than 400 mL of blood within the previous 3 months&#xD;
&#xD;
          -  Currently using glucocorticoids or have a history of systemic glucocorticoid use at&#xD;
             any dose within the last 12 months or 3 months for inhaled products&#xD;
&#xD;
          -  Additional criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazel Hunt, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

